Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)

NCT03298061 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03298061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03298061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
April 14, 2015
Completion date
February 16, 2023
Enrollment
100 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

churg-strauss syndrome, eosinophilic granulomatosis with polyangiitis